Remodulin and Scratch - a phase IV clinical study of FDA data

Summary:

Scratch is reported as a side effect among people who take Remodulin (treprostinil sodium), especially for people who are female, 50-59 old, also take Opsumit, and have Pulmonary hypertension.

The phase IV clinical study analyzes which people have Scratch when taking Remodulin. It is created by eHealthMe based on reports of 55,815 people who have side effects when taking Remodulin from the FDA, and is updated regularly.

What is Remodulin?

Remodulin has active ingredients of treprostinil sodium. It is often used in primary pulmonary hypertension. eHealthMe is studying from 55,843 Remodulin users. Check the latest studies of Remodulin.

What is Scratch?

Scratch is found to be associated with 688 drugs and 749 conditions by eHealthMe. Check the latest studies of Scratch.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

55,815 people reported to have side effects when taking Remodulin.
Among them, 35 people (0.06%) have Scratch.

Among these 35 people:

What is the gender of people who have Scratch when taking Remodulin? *

female: 71.43 %
male: 28.57 %

What is the age of people who have Scratch when taking Remodulin? *

What are other drugs people take besides Remodulin? *

What are other side effects people have besides Scratch? *

Itching: 18 people, 51.43%
Rashes (redness): 16 people, 45.71%
Catheter Site Haemorrhage (bleeding at catheter site): 13 people, 37.14%
Nausea (feeling of having an urge to vomit): 12 people, 34.29%
Dermatitis Contact (skin reaction (dermatitis) resulting from exposure to allergens): 9 people, 25.71%
Headache (pain in head): 9 people, 25.71%
Catheter Site Rash: 8 people, 22.86%
Infusion Site Pruritus (severe itching at infusion site): 7 people, 20.00%
Infusion Site Haemorrhage (bleeding from infusion site): 7 people, 20.00%
Infusion Site Erythema (reddening of the skin at infusion site): 7 people, 20.00%

What are the existing conditions these people have? *

Pulmonary Hypertension (increase in blood pressure in the lung artery): 4 people, 11.43%
Diabetes: 3 people, 8.57%
Thrombocytopenia (decrease of platelets in blood): 2 people, 5.71%
Cytomegalovirus Viraemia (cytomegalo virus in blood stream): 2 people, 5.71%

* Approximation only. Some reports may have incomplete information.

Do you take Remodulin and have Scratch?

- Check whether Scratch is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Remodulin:

Remodulin (55,843 reports)

Scratch treatments and more:

Scratch (10,633 reports)

Browse all side effects of Remodulin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Scratch:

Scratch (688 drugs)

Browse all the conditions that are associated with Scratch:

Scratch (749 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on treprostinil sodium (the active ingredients of Remodulin) and Remodulin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.